Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
Date:5/9/2013

development expenses as well as higher cost of goods related to increased product sales.

Research and development expense in the first quarter of 2013 was $45.6 million as compared to $35.1 million for the first quarter of 2012.  R&D expense was higher in the first quarter of 2013 reflecting the costs of the etirinotecan pegol (NKTR-102) BEACON Phase 3 study, the production of devices for the Phase 3 study of Amikacin Inhale, and Phase 2 studies for NKTR-181. 

General and administrative expense was $11.1 million in the first quarter of 2013 as compared to $10.4 million in the first quarter of 2012.

Non-cash interest expense was $5.5 million in the first quarter of 2013 as compared to $1.8 million in the first quarter of 2012.  The company incurred non-cash interest expense as a result of the sale of future royalties related to Cimzia® and Mircera®. 

Net loss for the first quarter of 2013 was $55.1 million or $0.48 loss per share as compared to $41.1 million or $0.36 loss per share in the first quarter of 2012.

The company also announced upcoming presentations at the following medical meetings and scientific congresses during the first half of 2013:

American Pain Society 32nd Annual Scientific Meeting, New Orleans, LA:

  • Poster: "NKTR-171: A Novel, Oral Sodium Channel Blocker That Exhibits Comparable Analgesic Efficacy to Pregabalin with Reduced Central Nervous System (CNS) Side Effects", Gursahani, H., et al. 
  • Date: May 9, 2013, 9:30 a.m. Eastern Time
  • Digestive Disease Week 2013, Orlando, FL:

  • Abstract 1594557: "Efficacy and Safety of Naloxegol in Patients with Opioid-Induced Constipation: Results from 2 Prospective, Randomized, Controlled Trials", Chey, W., et al. 
  • Date: May 21, 2013, 8:15 a.m. Eastern Time
  • Research Forum: New Pharmacological Treatments for Motility Disorders
  • 4th'/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
    2. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
    3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    5. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    6. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
    8. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
    9. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
    10. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
    11. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... Colo. , Nov. 25, 2014   Heska Corporation ... "Heska" or the "Company"), a provider of advanced veterinary ... Robert Grieve , Executive Chair, will attend The Benchmark ... 2014. The one-on-one conference will be held at The Palmer ... from 8 a.m. to 2:30 p.m. Please email ...
    (Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
    (Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
    Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
    ... SEOUL, South Korea, Dec. 5, 2011 /PRNewswire-Asia/ -- The ... Industry Development Institute announced that the Health Authority-Abu Dhabi ... National University Hospital, Asian Medical Center and Seoul St. ... a patient treatment-reference system in Abu Dhabi, on Nov. ...
    ... BEIJING, Dec. 5, 2011 /PRNewswire-Asia/ -- GC-Rise Pharmaceutical Co. ... holds a majority stake, was recently listed as one ... companies which rides on high growth over the past ... women,s health in China, saw its operating revenues rising ...
    Cached Medicine Technology:South Korea Signs Accord with Abu Dhabi Health Authority on Hospital Service Agreement 2Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
    (Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
    (Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
    (Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
    (Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
    (Date:11/27/2014)... (PRWEB) November 27, 2014 HealthPostures, ... office ergonomics equipment , has announced that it ... Commercial Office Environments. The partnership will put HealthPostures' ... furnishings location. , In addition to having its ... dealer partnership promotes HealthPostures' products with the business ...
    Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
    ... the number of seats in existing facilities to fill the ... the central government's proposed quota policy, says Chief Minister Arjun ... medical institutions and open more institutes in the state," said ... doctors and this was the only to "adjust the numbers". ...
    ... mosquito-transmitted viral fever, has claimed 12 lives in Betul district ... more districts//. ,'With three more deaths Sunday - two ... number of deaths allegedly due to Chikangunya fever in Betul ... here said Thursday. ,'The dead include a 10-year-old ...
    ... peripheral artery disease (PAD) patients have showed lesser death ... ,Researchers have also indicated that less physically active ... ,‘We found that there is a survival ... active in their daily routines,’ said Mary M. McDermott, ...
    ... can cause developmental delays in infants whose mothers were ... banned in the United States, officials in Africa plan ... malaria. ,According to study author Brenda Eskenazi, a ... the University of California, Berkeley, the potential benefits of ...
    ... that vaccines that contain mercury do not increase ... scientists examined patterns between the developmental disorder and ... in the journal Pediatrics. ,Their research ... children given shots after thimerosal, a mercury-based preservative, ...
    ... the All India Institute of Medical Sciences remained crippled ... to protest the move to sack its Director P ... were closed since last evening as resident doctors and ... apex body headed by Union Health Minister A Ramadoss ...
    Cached Medicine News:Health News:Chikungunya Death Toll Raises to 12 in Madhya Pradesh 2Health News:Physical Activity benefited Peripheral Artery Disease (PAD) patients 2Health News:Developmental Delays in Infants Linked to DDT 2
    ... This stool is unquestionably the finest operating ... especially for the ophthalmic surgeon who must ... A poor stool can unexpectedly shift resulting in ... solid base of five sturdy casters. A "foot ...
    This is a 2.5x focusing Galilean telescope with a range from 70cm to infinity. Ideal for use at sporting events, as well as for a wide range of hobbies....
    This 6x or 8x aspheric magnifier is fitted with a distance piece and is particularly useful for patients with tremor or focusing difficulties. The magnifier can be either spectacle mounted or hand h...
    All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
    Medicine Products: